Biased Ligands. Better Drugs.

Biased Ligand Products

CNS Portfolio

Target Indication Lead
Optimization
Preclinical
Development
Phase
1
Phase
2
Phase
3
Ownership
TRV130 Mu-opioid
receptor
Postoperative
Pain
intravenous Trevena Logo
TRV734 Mu-opioid
receptor
Moderate to
Severe Pain
oral Trevena Logo
Delta
Opioid
Delta-opioid
receptor
CNS   Actavis

Cardiovascular Program

Target Indication Lead
Optimization
Preclinical
Development
Phase
1
Phase
2
Phase
3
Collaborator
TRV027 Angiotensin II type 1 receptor Acute Heart Failure intravenous Actavis

Although Trevena's biased GPCR ligand technology is potentially applicable across a wide range of drug targets and diseases, our pipeline of wholly owned differentiated biased ligand drugs is currently focused on CNS diseases.

Copyright © Trevena, Inc.